Progression-free survival of SMM and symptoms at time of progression stratified by FLCr ≥100 or <100 and BMPC percentage ≥60 or <60
| . | All patients . | FLCR <100 . | FLCR ≥100 . | P . | BMPC <60 . | BMPC ≥60 . | P . |
|---|---|---|---|---|---|---|---|
| Patients, n | 273 | 156 | 27 | 251 | 22 | ||
| Progressed, n (%) | 123 (45) | 56 (36) | 15 (56) | 107 (43) | 16 (73) | ||
| Progression event, n (%)* | |||||||
| Hypercalcemia | 4 (3) | 2 (4) | 0 (0) | 1.0000 | 4 (4) | 0 (0) | 1.0000 |
| Renal insufficiency | 11 (9) | 2 (4) | 3 (20) | .0599 | 11 (10) | 0 (0) | .3560 |
| Anemia | 62 (50) | 33 (59) | 10 (67) | .7677 | 52 (49) | 10 (63) | .2996 |
| Bone disease | 64 (52) | 25 (45) | 8 (53) | .5742 | 55 (51) | 9 (56) | .7173 |
| . | All patients . | FLCR <100 . | FLCR ≥100 . | P . | BMPC <60 . | BMPC ≥60 . | P . |
|---|---|---|---|---|---|---|---|
| Patients, n | 273 | 156 | 27 | 251 | 22 | ||
| Progressed, n (%) | 123 (45) | 56 (36) | 15 (56) | 107 (43) | 16 (73) | ||
| Progression event, n (%)* | |||||||
| Hypercalcemia | 4 (3) | 2 (4) | 0 (0) | 1.0000 | 4 (4) | 0 (0) | 1.0000 |
| Renal insufficiency | 11 (9) | 2 (4) | 3 (20) | .0599 | 11 (10) | 0 (0) | .3560 |
| Anemia | 62 (50) | 33 (59) | 10 (67) | .7677 | 52 (49) | 10 (63) | .2996 |
| Bone disease | 64 (52) | 25 (45) | 8 (53) | .5742 | 55 (51) | 9 (56) | .7173 |
Total number of progression events exceeds the number of patients who progressed as patients may have progressed by multiple events.